关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东云南国际信托有限公司－聚利 36 号单一资金信托保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 持有海南海药股份有限公司（简称"本公司"）股份 107,216,412 股（占本 公司总股本比例 8.26%）的股东云南国际信托有限公司－聚利 36 号单一资金信 托（简称"云南国际信托"）计划在本公告披露之日起 15 个交易日后的连续 90 个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过 38,920,953 股，占本公司总股本的 3%；其中，通过集中竞价交易减持不超过 12,973,651 股 （占本公司总股本比例 1%）；通过大宗交易方式减持不超过 25,947,302 股（占 本公司总股本比例 2%）。 一、减持主体的基本情况 1、股东名称：云南国际信托有限公司－聚利 36 号单一资金信托 证券代码：000566 证券简称：海南海药 公告编号：2025-038 2、股东持股情况：截至本公告日，云南国际信托持有本公司股份 107 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-037 海南海药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 二、会议召开的情况 现场会议召开时间：2025年5月9日下午15：00 网络投票时间：2025年5月9日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年5月9日9：15～ （2）通过深圳证券交易所互联网投票系统投票的时间为2025年5月9日9:15～15:00 期间的任意时间。 北京大成(海口)律师事务所见证律师对本次股东大会进行见证，并出具法律意见书。 《关于召开 2024 年年度股东大会的通知》，本次股东大会的内容及大会召集、召开方式、 程序均符合《公司法》《股票上市规则》及《公司章程》的有关规定。 三、会议的出席情况 本次股东大会以现场投票和网络投票相结合的表决方式对列入会议审议的议案进 行了表决，具体表决结果如下： （一）审议通过了《关于 2024 年度董事会工作报告的议案》 总表决情况： 同意 427,102,481 股，占出席会议所有股东所持表决权股份的 99.8218%； ...

北京大成（海口）律师事务所 关于海南海药股份有限公司2024年年度股东大会的 法律意见书 大成isDentons' PreferredLawFirminChina. 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于海南海药股份有限公司2024年年度股东大会 的法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2024年年度股东大会（以 下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格 、召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议 的议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本 次股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东大会相关事项的合法性之目的使用，不 得 ...

北京大成（海口）律师事务所 关于海南海药股份有限公司2024年年度股东大会 的法律意见书 大成isDentons' PreferredLawFirminChina. 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于海南海药股份有限公司2024年年度股东大会的 法 律 意 见 书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2024年年度股东大会（以 下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格 、召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议 的议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本 次股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东大会相关事项的合法性之目的使用 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-037 海南海药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 1、召开时间： 现场会议召开时间：2025年5月9日下午15：00 网络投票时间：2025年5月9日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年5月9日9：15～ 9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年5月9日9:15～15:00 期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司第十一届董事会 5、现场会议主持人：公司第十一届董事会董事长王建平先生 三、会议的出席情况 1 1、参加现场会议和网络投票的股东 337 人，代表股份 427,864,881 ...

Group 1 - Dashi Intelligent signed a smart hospital project contract worth 58.12 million yuan with the First Affiliated Hospital of Bengbu Medical College and Bengbu Urban Construction Investment Development Co., Ltd. [1] - The project aims to create a comprehensive tumor specialty hospital integrating medical care, research, teaching, preventive health care, and rehabilitation, which is expected to positively impact the company's future performance [1] Group 2 - Huahong Company reported a net profit of 22.76 million yuan for Q1 2025, a year-on-year decrease of 89.73%, despite a revenue increase of 18.66% to 3.913 billion yuan [2] - The company specializes in the development and application of embedded/non-volatile memory, power devices, and other semiconductor technologies [2] Group 3 - Jindi Group announced a signed area of 214,000 square meters in April, a year-on-year decrease of 55.14%, with a signed amount of 2.78 billion yuan, down 55.45% [3] - The company focuses on real estate development and sales, commercial real estate, and property management [3] Group 4 - Jinlong Automobile reported a bus production of 4,361 units in April, a year-on-year decrease of 5.79%, with sales of 3,611 units, down 3.91% [4][5] - The company is engaged in the production and sales of bus products [5] Group 5 - Sanyou Medical established a joint venture with CGBio Co., Ltd. with a registered capital of 60 million yuan, focusing on innovative cell biological materials and regenerative medicine [6][7] - The company specializes in the research, production, and sales of orthopedic implant consumables [7] Group 6 - Jinzhi Technology won a bid for projects related to the State Grid with a total amount of 90.73 million yuan, accounting for 5.12% of the company's projected revenue for 2024 [9][10] - The company focuses on smart energy and smart city businesses [10] Group 7 - Pinggao Electric won multiple procurement projects from the State Grid, totaling approximately 1.751 billion yuan, which is 14.12% of the company's projected revenue for 2024 [10] - The company specializes in high-voltage switchgear and power engineering contracting [10] Group 8 - Luantang Pharmaceutical received approval for the raw material drug Celecoxib, which is a selective COX-2 inhibitor with fewer gastrointestinal side effects compared to traditional NSAIDs [11][12] - The company is involved in the research, production, and sales of pharmaceutical products [12] Group 9 - Dongjie Intelligent obtained seven patent certificates related to AGV and conveyor system technologies [13][14] - The company specializes in the research, design, manufacturing, installation, and debugging of intelligent logistics systems [14] Group 10 - XJH Holdings received a government subsidy of 8.69 million yuan, which accounts for 38.67% of the company's projected net profit for 2024 [15][16] - The company focuses on the recycling and dismantling of waste electrical products [16] Group 11 - Huaihua Pharmaceutical's subsidiary received approval for the clinical trial of HZ-J001 ointment for treating non-segmental vitiligo [17][19] - The company is engaged in the research, production, and sales of pharmaceutical products [19] Group 12 - ST Aonong reported a pig sales volume of 132,800 heads in April, a year-on-year decrease of 14.42%, while the stock of pigs increased by 15.06% [22][23] - The company is involved in feed, pig farming, food, and trade [23] Group 13 - Beibu Gulf Port reported a cargo throughput of 31.75 million tons in April, a year-on-year increase of 20.32% [24][25] - The company specializes in port loading, storage, and related services [25] Group 14 - Dongfang Iron Tower won a bid for State Grid projects totaling approximately 100 million yuan, which is 2.39% of the company's projected revenue for 2024 [26] - The company focuses on steel structures and related businesses [26] Group 15 - Huanxu Electronics reported a consolidated revenue of 4.641 billion yuan in April, a year-on-year increase of 0.72% [27] - The company provides design, manufacturing, and related services for brand customers [27] Group 16 - Jincheng Co. announced that part of its bank accounts has been frozen, involving approximately 32.97 million yuan due to contract disputes [28][29] - The company specializes in high-end intelligent equipment for photovoltaic and smart port sectors [29] Group 17 - NAIKE Equipment announced the departure of core technical personnel Wang Xiangguo [30][31] - The company focuses on semiconductor packaging equipment and related products [31] Group 18 - Jiaojian Co. won a construction project in Hefei with a bid amount of approximately 704 million yuan, covering residential buildings and related infrastructure [32][33] - The company specializes in infrastructure construction and related services [33] Group 19 - Hongyuan Green Energy plans to transfer a 27.07% stake in Inner Mongolia Xinyuan Silicon Material Technology Co., Ltd. for 1.245 billion yuan [34][35] - The company focuses on the research, production, and sales of aviation electromechanical products [35] Group 20 - Poly Development reported a signed amount of 24.622 billion yuan in April, a year-on-year decrease of 25.44% [46][48] - The company specializes in real estate development and sales [48]

Group 1 - Geely Auto proposed to privatize Zeekr with an offer of $2.57 per share, representing a 13.6% premium over the last trading price [1] - The offer also includes a premium of 20.0% over the volume-weighted average price of the last 30 trading days [1] - Geely currently holds approximately 65.7% of Zeekr's issued share capital [1] Group 2 - Sun Group announced the U.S. Department of Commerce has revoked its investigation into steel wheels made in Vietnam using Chinese components [2] - The revocation is expected to positively impact the company's export orders and future overseas business layout [2] Group 3 - Qingdao Beer plans to acquire 100% equity of Jimo Yellow Wine for a total consideration of RMB 665 million [3] - The acquisition aims to enhance industry synergy, competitiveness, and expand product lines and market channels [3] Group 4 - BeiGene reported a net loss of 94.503 million yuan in Q1 2025, a reduction in loss compared to the previous year [4] - The company achieved total revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, driven by sales growth of its self-developed products [4] Group 5 - Daqin Railway reported a 0.99% year-on-year increase in cargo transportation volume for April [5] - Shaanxi Coal's self-produced coal sales reached 13.1033 million tons in April, up 0.76% year-on-year [5] Group 6 - Shennong Group sold 227,300 pigs in April, marking a 32.85% year-on-year increase [6] - Poly Developments reported a 25.44% year-on-year decrease in contracted sales amounting to 24.622 billion yuan in April [6] Group 7 - Hainan Development plans to acquire 51% equity of Wangying Technology [7] - Huafeng Measurement Control's shareholders plan to transfer 2.9% of shares at an initial price of 121.42 yuan per share [7] Group 8 - Various companies reported significant stock price fluctuations, with Changshan Pharmaceutical's injection not yet on the market and facing regulatory uncertainties [8] - The company is in the professional review stage for its diabetes treatment application [8]

证券代码：000566 证券简称：海南海药 公告编号：2025-035 海南海药股份有限公司关于参加 "2024年度海南辖区上市公司业绩说明会暨投资者集体接待日" 的公告 海南海药股份有限公司 董 事 会 二〇二五年五月八日 1 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "2024 年度海南辖区上市公司业绩说明会暨投资者集体接待日"活动，活动时 间为 2025 年 5 月 13 日 14:00-17:00，平台登陆地址为：https://rs.p5w.net。 届时，海南海药股份有限公司（以下简称"公司"）主要高管人员将参加本 次活动，通过网络在线交流形式，就公司 2024 年年报披露、财务数据、公司治 理、内部控制、发展战略、经营状况、现金分红、重大事项、可持续发展等投资 者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者 踊 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-036 海南海药股份有限公司关于 控股子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）控股子公司重 庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺 拉生《化学原料药上市申请批准通知书》（通知书编号：2025YS00357）。现将 相关情况公告如下： 一、产品基本情况 | 化学原料药名称 | 通用名称 ：富马酸伏诺拉生 | | --- | --- | | | 英文名/拉丁名：Vonoprazan Fumarate | | 化学原料药注册 标准编号 | YBY64172025 有效期 18 个月 | | 包装规格 | 25kg/桶 | | 申请事项 | 境内生产化学原料药上市申请 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 | | | 合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照 | | | 所附执行。 | | 生产企业 | 重庆天 ...

Group 1: Drug Development and Clinical Trials - Pinegabine is being developed using a stepwise approach, first assessing its efficacy in combination therapy before evaluating its effectiveness as a monotherapy [2] - The company is currently conducting Phase IIa clinical trials for Pinegabine, with low-dose cohort enrollment completed and mid-dose cohort enrollment ongoing [2] - Pinegabine is positioned as a me-better drug compared to Retigabine, which was withdrawn from the market due to safety concerns [3] Group 2: Market Analysis and Product Characteristics - Epilepsy is the second most common neurological disorder after stroke, with a significant portion of patients experiencing treatment-resistant epilepsy [4] - There is a lack of innovative antiepileptic drugs in recent years, particularly for special types of epilepsy and acute seizures [4] - Pinegabine demonstrates superior chemical stability and higher brain distribution compared to Retigabine, enhancing its efficacy and safety profile [4] Group 3: Patent and Market Strategy - The patent for Pinegabine is held by the Shanghai Institute of Materia Medica, with exclusive rights for clinical development and commercialization in mainland China [5] - The company plans to explore international rights transfer and partnerships based on the outcomes of Phase II clinical trials [5] Group 4: Future Prospects and Expansion - Pinegabine may expand its indications based on Phase II clinical results and market needs, potentially targeting conditions like severe depression due to KCNQ mutations [4] - Fluorofenone, another drug in development, is expected to enter Phase III clinical trials in the second half of 2025, having been included in the breakthrough therapy list by the National Medical Products Administration [6] - The company aims to focus on anti-fibrosis indications initially, with potential future expansions depending on clinical trial outcomes [6]